Ah... the problem here is not that the pharma companies aren't getting paid.. The problem is there's a bunch of banks and government subsidies and a lot of middle-people creating cost on top of enabling the funds flow. I am not sure what's the solution, but there really are a lot of administrative middle-people involved..